Background. Cannabis use is common in North America, especially among young people,
and is associated with a risk of various acute and chronic adverse health outcomes …

The golden age of cannabis pharmacology began in the 1960s as Raphael Mechoulam and
his colleagues in Israel isolated and synthesized cannabidiol, tetrahydrocannabinol, and …

In an increasing number of states and countries, cannabis now stands poised to join alcohol
and tobacco as a legal drug. Quantifying the relative adverse and beneficial effects of …

Schizophrenia risk has often been conceptualized using a model which requires two hits in
order to generate the clinical phenotype—the first as an early priming in a genetically …

Abstract Background and Aims Cannabis products are becoming increasingly diverse, and
vary considerably in concentrations of∆ 9‐tetrahydrocannabinol (THC) and cannabidiol …

The legal status of Cannabis is changing, fueling an increasing diversity of Cannabis-
derived products. Because Cannabis contains dozens of chemical compounds with potential …

Cannabis products have recently regained much attention due to the high pharmacological
potential of their cannabinoid content. In this review, the most widely used sample …

Epidemiological evidence demonstrates that cannabis use is associated with an increased
risk of psychotic outcomes, and confirms a dose‐response relationship between the level of …

The cannabis withdrawal syndrome (CWS) is a criterion of cannabis use disorders
(CUDs)(Diagnostic and Statistical Manual of Mental Disorders–Fifth Edition) and cannabis …

Abstract The global Cannabis Sativa market, including essential oils, foods, personal-care
products, and medical formulations has gained much attention over the last years due to the …